Genome-wide Profiling Using Single-Nucleotide Polymorphism Arrays Identifies Novel Chromosomal Imbalances in Pediatric Glioblastomas by Qu HQ et al.
Genome-wide profiling using single-
nucleotide polymorphism arrays identifies
novel chromosomal imbalances in pediatric
glioblastomas
Hui-Qi Qu*, Karine Jacob*, Sarah Fatet, Bing Ge, David Barnett, Olivier Delattre,
Damien Faury, Alexandre Montpetit, Lauren Solomon, Peter Hauser, Miklos Garami,
Laszlo Bognar, Zoltan Hansely, Robert Mio, Jean-Pierre Farmer, Steffen Albrecht,
Constantin Polychronakos, Cynthia Hawkins, and Nada Jabado
Departments of Paediatrics and Human Genetics, Montreal Children’s Hospital (H.-Q.Q., C.P.); Division of
Hemato-Oncology, Departments of Paediatrics and Human Genetics, Montreal Children’s Hospital Research
Institute (K.J., D.B., D.F., N.J.); Molecular Diagnostic Laboratory, Department of Genetics, Montreal Children’s
Hospital Research Institute (R.M.); Division of Neurosurgery, Montreal Children’s Hospital (J.-P.F.);
Department of Pathology, Montreal Children’s Hospital, McGill University Health Centre, Montreal, Canada
(S.A.); INSERM U 830, Institut Curie, Paris, France (S.F., O.D.); McGill University and Genome Quebec
Innovation Centre, Montreal, Canada (B.G., A.M.); Division of Pathology, The Hospital for Sick Children,
Toronto, Canada (L.S., C.H.); 2nd Department of Paediatrics, Faculty of Medicine, Semmelweis University,
Budapest, Hungary (P.H., M.G.); Division of Neuro-Surgery, Division of Pathology, National Institute of
Neurosurgery, Budapest, Hungary (L.B.); Department of Neurosurgery, Medical and Health Science Centre,
University of Debrecen, Debrecen, Hungary (Z.H.)
Available data on genetic events in pediatric grade IV
astrocytomas (glioblastoma [pGBM]) are scarce. This
has traditionally been a major impediment in under-
standing the pathogenesis of this tumor and in develop-
ing ways for more effective management. Our aim is to
chart DNA copy number aberrations (CNAs) and get
insight into genetic pathways involved in pGBM.
Using the Illumina Infinium Human-1 bead-chip-array
(100K single-nucleotide polymorphisms [SNPs]), we
genotyped 18 pediatric and 6 adult GBMs. Results
were compared to BAC-array profiles harvested on 16
of the same pGBM, to an independent data set of 9 pedi-
atric high-grade astrocytomas (HGAs) analyzed on
Affymetrix 250K-SNP arrays, and to existing data sets
on HGAs. CNAs were additionally validated by real-
time qPCR in a set of genes in pGBM. Our results ident-
ify with nonrandom clustering of CNAs in several novel,
previously not reported, genomic regions, suggesting
that alterations in tumor suppressors and genes involved
in the regulation of RNA processing and the cell cycle
are major events in the pathogenesis of pGBM. Most
regions were distinct from CNAs in aGBMs and show
an unexpectedly low frequency of genetic amplification
and homozygous deletions and a high frequency of loss
of heterozygosity for a high-grade I rapidly dividing
tumor. This first, complete, high-resolution profiling of
the tumor cell genome fills an important gap in studies
on pGBM. It ultimately guides the mapping of onco-
genic networks unique to pGBM, identification of the
related therapeutic predictors and targets, and develop-
ment of more effective therapies. It further shows that,
despite commonalities in a few CNAs, pGBM and
aGBMs are two different diseases.
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Introduction
B
rain tumors are the largest group of solid neo-
plasms in children and are currently the leading
cause of cancer-related mortality and morbidity
in the pediatric years. Pediatric high-grade astrocytomas
(HGAs), including grade IV astrocytomas (glioblastoma
[GBM]) account for 15% of all brain neoplasms in chil-
dren,1 have a dismal prognosis despite aggressive man-
agement, and have a high morbidity linked to current
treatments. Although their diagnosis still relies mainly
on pathology, little is known about the molecular mech-
anisms underlying their development.
Physical changes in the DNA copy number of particu-
lar genomic regions, manifesting as loss of heterozygos-
ity (LOH) or epigenetic changes such as loss of
imprinting, have been shown to promote cancer for-
mation and progression. In particular, LOH has been
extensively used in the discovery of various tumor
suppressor genes, including Rb1 and p53. A precise
characterization of these genomic alterations in a given
tumor may therefore increase our understanding of the
oncogenic events promoting its growth and may
provide more accurate means for its classification.
However, most of the work done to date on nonrandom
LOH in solid tumors has been based on searches for a
small number of candidate loci. Comparative genomic
hybridization (CGH), which identifies chromosomal
segments with copy number changes (gain or loss),2–4
has an effective resolution that varies from 20 Mb to
100 kb and a far from optimal capacity in detecting
chromosomal deletions, especially LOHs.5 More
recently, a major breakthrough for the precise mapping
of genomic aberrations in cancers has been made by
the completion of the human genome sequence.6
Concurrently, high-density arrays for genotyping single-
nucleotide polymorphisms (SNPs)6,7 have been made
available (reviewed in Ref. 8). These arrays combine
the genome-wide potential of hybridization arrays with
higher-resolution (by an order of magnitude) detection
of LOH, DNA copy number alterations, and other
chromosomal aberrations compared to CGH.
Studies using these high-resolution arrays can
be applied to unravel, with high precision, genomic
imbalances in HGAs while providing an additional
tool to classify these tumors. They have been used in
adult HGAs (aHGAs, mainly high-resolution CGH
arrays), providing more accurate tools for prognosis
and the identification of therapeutic targets in this
tumor.9 – 15 Genomic alterations involved in pHGAs
are largely unknown, with only a few published
studies using lower-resolution arrays.16 – 18 Moreover,
pHGAs have distinct molecular profiles from aHGAs,
indicating that results from adult studies cannot be
applied to children.19,20 To identify genetic loci specifi-
cally involved in pHGAs, we analyzed 18 pediatric
GBMs and 6 aHGAs using high-resolution Illumina
100K SNP arrays and an independent data set of
9 pHGAs using the Affymetrix 250K SNP arrays
platform.
Materials and Methods
Sample Characteristics and Pathological Review
All samples were obtained under a protocol approved
by the hospitals’ institutional review boards and
independently reviewed by senior pediatric neuro-
pathologists (S.A. and C.H.) to ensure consistent classi-
fication based on contemporary guidelines from the
World Health Organization. Eighteen pGBMs (average
10.3+5.2 years) and 6 aGBMs (average 58.8+18.2
years) were analyzed using the Illumina platform.
Snap-frozen sections of areas immediately adjacent to
the regions used for pathological diagnosis were pro-
vided and contained vascular tissue ranging from
,10% to 30% of the full section. Normal tissue was
not available for any of the samples. Tissues were
obtained from the Pediatric Cooperative Human
Tissue Network, the London/Ontario Tumor Bank,
and from collaborators in Montreal and Toronto
(Canada) and Hungary. Clinical findings of patients
are provided in Table 1. Adult samples have
previously been reported for gene expression analysis
of pGBM.19
DNA Extraction and Hybridization
DNA from frozen tumors was extracted as described pre-
viously.16 DNA (250 ng) from 25 samples was assayed
with Infinium I whole genome genotyping, according to
the recommendations of the manufacturer (Illumina,
San Diego, CA, USA). The Illumina Sentrix Human-1
Genotyping BeadChip covers 109,365 gene-centric
SNPs over the genome with a mean intermarker distance
of 26 kb (13 kb median spacing). Image intensities were
extracted using Illumina’s BeadScan software. Data for
each BeadChip were self-normalized using information
contained within the array. For Affymetrix 250K SNP
chips, 250 ng of tumor DNA was processed according
to the manufacturer (Affymetrix, Inc., Santa Clara, CA,
USA) and data were analyzed as described elsewhere.16
Genome profiles were created using the Illumina
Genome Viewer and Chromosome Browser, which
allow viewing, identifying, and manually annotating the
chromosomal aberrations. For the initial analysis, the
output by BeadStudio software was used to interpret the
nature of the aberration. These variables include the nor-
malized intensity of hybridization, expressed as its base-2
logarithm (log2 R), and the allelic ratio, expressed as the
ratio of one allele over the sum of both alleles.21
Visualization of copy number and LOH in normal
tissues is performed by plotting the log2R and the allele
ratios across the genome. This algorithm, however,
assumes single-lineage DNA and could not be used
alone with these tumor tissue samples, which are unavoid-
ably mixed with normal vascular tissue. Amplifications
were therefore detected if there was an increase in the
log2 R value (1, corresponding to tetraploid copy
number ie 4). The SNPs with log2 R  2 in tumor
tissues, but with normal log2 R in all CEU (CEPH
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European) DNA samples analyzed in the HapMap
project were taken as homozygous deletions.21 If
log2 R  2 in the CEU samples, the marker was discarded
as a failed assay. To identify heterozygous deletions, we
estimated the LOH score using the genotypes of all
SNPs in a sequence window of 1 Mb, around any
marker. This score is the base-10 logarithm of the ratio
of the probability of observing the genotypes of all
SNPs in the presence of LOH over the probability of
observing the same genotype in the absence of LOH. It
is based on the allele frequencies observed in the
European-ancestry subjects used in the HapMap project
(CEU set) and assigned to the marker in the middle of
the window.22 We considered that a score of more than
10 is diagnostic of LOH. Four DNA samples from the
CEU set were used as the normal control in the same
assay.
BAC Arrays
The CGH-array analysis of tumor samples was per-
formed as described previously.23 The V5S2 genomic
array uses 3913 BAC markers from across the human
genome with a mean resolution of 1 Mb.
Normalization and data analyses were done with
VAMP software (Bioinformatics Department, Curie
Institute, Paris, France).23 Fluorescence ratios exceeding
1.2 were considered indicative of gains of chromosomal
material, whereas losses were indicated by ratios lower
than 0.8.
Validation of Copy Number Changes by Quantitative
Real-Time PCR
Quantitative real-time PCR was done on an ABI-Prism
7000 sequence detector (Applied Biosystems) using a
SYBR Green kit (Applied Biosystems). The target locus
from each tumor DNA was normalized to the reference,
Line-1 as previously described.16
Statistical Analysis
To be considered causative, a somatic copy-number
change must be non-random, that is, recur at the same
locus in different tumors more frequently than expected
by chance alone. To assess the statistical significance of
the occurrence of such overlaps in different tumors,
their number was compared to a distribution generated
by cyclically permuting the position of the LOH
regions on each chromosome of each tumor 10,000
times. The false-detection rate (FDR) was calculated as
the proportion of overlaps in any given number of
tumors that would be expected to occur by chance
alone (see Supplementary Material, Fig. S1).
Results
Genomic Alterations Identified in BAC and in SNP
Arrays in 16 pGBM Samples
We used a previously validated BAC-array platform,
which has provided numerous results in tumor LOH
studies,23 and investigated the concordance of copy
number aberration (CNA) detection between this plat-
form and the Illumina 100K SNP arrays in 16 pHGAs
(P1–P16; Table 1). BAC-array results validated data
obtained by SNP arrays (see Supplementary Material,
Table S1). However, because of the higher resolution
of the SNP arrays, a higher number of alterations,
left undetected by the BAC arrays, were uncovered.
This is in keeping with previous findings on the higher
sensitivity of SNP technology for the detection of
CNAs.24
CNAs in pGBM and aGBMs Detected Using Illumina
SNP Arrays
Analysis of the data set of 18 pGBMs and 6 aGBMs
using the Illumina SNP arrays showed that heterozygous
deletions, detected as LOH, are common phenomena
mostly in pGBM and were seen for each chromosome
in a number of samples (Tables 1–4; see also
Table 1. Clinical characteristics of GBM samples from adult and
pediatric patients analyzed using the Illumina 100K SNP array
GBM Gender Age at Diagnosis
(Years)
Tumor Location
Pediatric
P1 M 9 Infratentorial
P2 F 6 Supratentorial (frontal)
P3 F 10 Supratentorial (parietal)
P4 F 14 Supratentorial (parietal)
P5 M 14 Supratentorial (frontal)
P6 M 14 Supratentorial (temporal)
P7 F 9 Supratentorial (multilobar)
P8 M 3 Supratentorial (temporal)
P9 F 11 Supratentorial (temporal)
P10 F 13 Supratentorial (frontal)
P11 M 7 Supratentorial (thalamic)
P12 F 16 Infratentorial
P13 M 16 Infratentorial
P14 M 13 Infratentorial
P15 M 15 Infratentorial
P16 F 12 Supratentorial (parietal)
P17 F 10 Infratentorial
P18 M 13 Mixed
Adult
Secondary
A1 M 52 Supratentorial (multilobar)
A2 F 49 Supratentorial (frontal)
A3 M 67 Supratentorial (thalamic)
Primary
A4 F 30 Supratentorial (parietal)
A5 M 70 Supratentorial (temporal)
A6 F 82 Supratentorial (frontal)
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Supplementary Material, Table S1). Despite common
LOH regions between pGBM and aGBM such as
9p24.3-9p13.1 and 17p13.3, there was little concor-
dance between the CNAs detected in both settings,
with most LOHs (Tables 3 and 4), amplifications
(Table 5), and homozygous deletions (Table 6) found
in children being different from the ones encountered
in adults (Tables 2–6). Unsupervised hierarchical
clustering analysis, using as input data regions with
CNAs in at least one sample, clustered the aGBM
samples separately from most pGBMs and the normal
brain, confirming the presence of distinct molecular
imbalances specific to pGBM.19 Interestingly, it also sep-
arated primary from secondary aGBMs (Fig. 1).
Analysis of Recurrent Regional LOH in GBMs
Several overlapping regions of LOH in tumors were
identified in pGBM samples (Tables 3 and 4). By permu-
tation analysis, the 95% confidence interval of the FDR
for seven tumor-overlaps is 0–0.096, which makes it
unlikely that more than one of these overlaps is the
result of chance alone (see Supplementary Material,
Fig. S1). Some of these LOHs found in more than seven
samples have been previously described, but most are
novel (Tables 2–4). The highest LOH frequency peak
in pGBM was from a 103-kb cluster located in
Chr15q15 (10/18) (Tables 3 and 4). Novel genes, includ-
ing protein p53 binding protein 1 (TP53BP1) and Cyclin
Table 2. CNAs identified in 18 pGBMs and aGBMs using the 100K SNP Illumina array
Tumors No of
CNAs
CNAs
P1 1 (2)22q
P2 12 (2)2q11-13, (2)9p24-21, (2)10p12-11, (2)10q, (2)14q23-32, (2)15q15-14, (2)16q, (2)17p,
(þ)17q21-25, del17q11, (2)19q, del21q11-21
P3 2 (2)12q24, (2)22q
P4 38 (2)2p25-11, (2)3q21-29, (2)4p16-13, (2)4p12, (þ)4p13, (þ)4p12, (2)4q13-35,(þ)4q12, (þ)5p33-15,
(þ)5p15-12 (2)5p15, (2)5q11-21, (2)5q31-32, (del)6q24, (2)7p, (2)7q, (þ)7q31, (2)9p22-21,
(þ)9p24, (þ)9p23-22, (þ)9p21-13, (þ)10p12, (2)10q11-23, (þ)10q23-24, (2)10q24-26,del11q11-22,
del11q22-23, (2)12q21-23, (2)13q, (2)14q, del16q23, (2)17p13-17q11, (2)18p, (2)18q, (2)19p13,
(þ)19p13, (2)20q, (2)22q
P5 4 (þ)2p24, (þ)11p, (2)11q13-25, (þ)17q21-24
P6 6 (þ)1q, (2)8p23, (2)9p, (þ)9q, (þ)21q21, (2)22q12-13
P7 23 (2)3p, (2)3q, (2)4p, (2)4q, (2)5p, (2)5q, (2)6p, (2)6q, (þ)7q21, (2)8p, (2)8q, (þ)9q33-34, (2)10p,
(þ)10p12, (2)10q, (þ)13q14, (þ)13q31, (þ)13q33-34, (2)15q, (2)17p, (2)17q, (2)19p13, (2)22q
P8 33 (þ)1q43-44, (2)2p24-23, (þ)2p25, (þ)2p24.3, (þ)2p24.1, (þ)2p23.1, (2)3p, (2)3q,(þ)3q26, (2)4p,(2)4q,
(2)5p, (2)5q, (2)6p, (2)6q, (þ)7p11, (þ)7q21, (þ)7q21, (þ)7q31, (þ)7q33, (2)8p, (2)8q, (2)10p,
(2)10q, (2)11p15, (2)11q13-23
(2)14q, (2)15q, (2)17p, (2)17q, (2)18p, (2)18q, (2)22q
P9 33 (2)1p, (2)1q, (2)2p, (2)2q, del2q21-22, (2)3p, (2)3q, (2)4q32-35, (2)5q15-35, (2)6p, (2)6q,
(2)8q11-24, (2)8q24, (2)9p, del9p23, del9p21, (2)9q, (2)10p, (2)10q, (þ)10q26, (2)11p, (2)11q,
(2)13q, (2)14q, (2)16p, (2)16q, (2)17p, (2)17q, (2)18p, (2)18q, (2)20p, (2)20q, (2)21q
P10 17 (2)2p, (2)3q12-27, (þ)3q26-29, (2)4q31, (þ)7p, (þ)7q, (2)8p21-12, (2)8p12-11, (2)9p21-13, 9q31-33,
(2)10p, del 10q21-22, (2)10q25-26, (2)11q22-24, (2)14q31-32, (2)17p13, (2)19q13
P11 4 (2)1p, (2)6q12-13, (þ)6q14, (2)6q14-27
P12 4 (2)10q21-26, (2)15q12-26, (2)16p, (þ)17p13
P13 15 del1q24-31, (þ)5p15, (þ)7p22, (þ)7p21, (þ)7p21, (2)9p24-22, (2)9p21, (2)10q23-26, (þ)10q22,
(þ)10q23, (2)16q, (2)17p, (2)18q12-23, (2)20p, (2)21q
P14 1 (2)22q
P14 4 (þ)2p24, (þ)4q12, (þ)7p, (þ)7q
P16 1 (þ)9p21-13
P17 1 (þ)7q11
P18 0
A1 10 (þ)3p11-12, (2)3p26-24, (2)3q27-28, (2)3q29, (2)9p, del9p22-21, (2)9q12-21, (2)10p, (2)10q,
(2)22q12-13
A2 14 (2)3p26, (2)9p24-21, (2)9p21, (2)9p13, (2)9q22, (2)11p15, 12p13-12, (2)13q12-21, del 14q23,
del14q24, (2)10p, (2)10q, (2)17p13, (2)19q13, (2)21q, (2)22q13
A3 3 (2)4q13-35, (2)9p24-21
A4 4 (þ)7p11-14; del 9p22-21, (2)10q, (þ)12q13-15, (2)19p12
A5 9 (2)5q, (2)7q11-21, (2)11p15-11, (2)12p, (2)13q, (2)14q, (2)17p13-11, (2)18p11, (2)21q22
A6 2 (þ)7p14-15, (þ)7p11-15, (2)10q
A, adult glioblastoma; P, pediatric glioblastoma. (2) indicates an LOH; (þ) indicates an amplification or gain; “del” indicates a
homozygous deletion.
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Table 3. LOH analysis showing distinct imbalances between pGBM and aGBM
Cytogenetic Band Locus (Mb) Minimal Region Genes Number of
Tumors
Known or Novel Interesting Genes
Start SNP Position End SNP Position
LOH regions in 19 pGBMs
2p25.3-2p11.2 rs876724 104974 rs4832054 86970238 2p24.1-2p23.1 100 4 Novel
3q12.1-3q29 rs7614366 100979041 rs7374380 199195232 3q21.1-3q26 361 5 Novel
4q13.1-4q35.2 rs1449043 59562234 rs1317423 191081281 4q32.3-4q35.2 137 5 Novel
5q11.1-5q21.3 rs4865676 49610934 rs7701086 109419588 5q11.1-5q21.3 348 4 Novel
6q12-6q27 rs9363741 68085762 rs2021899 170823609 6q12-6q27 630 4 Novel
8p23.3-8p11.21 rs888580 204809 rs907561 40930754 8p23.3-8p11.21 373 4 Novel
9p24.3-9p13.1a rs493348 202421 rs7848575 38708308 9p24.3-9p22.1 92 5 Known ELAVL2 CDKN2A CDKN2B
10p 10p12.31-10p11.1 133 5 Novel
10q22.1-10q26.3 rs10762360 71729512 rs2803990 134410330 10q22.1 1 7 Novel CBARA1
11q13.2-11q25 rs3133269 67560732 rs4300405 133977871 11q22.1-11q23.1 107 4 Novel
14q23.3-14q32.33 rs1290900 66770921 rs7492357 105033704 14q31.3-14q32.31 189 5 Novel
15q15.1-15q23 rs2289218 38853018 rs10220851 66092261 15q15.2-15q15.3 13 10 Novel CCNDBP1 TP53BP1 H76p
16q 16q 4 Known
17p13-17p11.2 rs2750007 623976 rs4924750 18201478 17p13.3a 3 7 Novel SMYD4 RPA1
17p13.1 2 7 Novel CLEC10A ASGR2
17p13.1 79 7 Novel GPS2
18q12.2-18q23 rs1484095 33971576 rs4798947 76064957 18q23 19 4 Novel KCNG2
22q11.1-22q13 rs3788277 16054103 rs6520165 49144461 22q12.2 1 7 Novel NF2
22q12.3 7 7 Novel KCTD17
22q13.1 18 7 Novel RAC2 CDC42EP1
22q13.1 9 7 Novel LOC400927 TPTE, PTEN homologs
LOH regions in 6 aGBMs
3p26.3-3p24.2 rs6803398 982443 rs892940 24513842 3p26.3 4 2 Novel CHL1
9p24.3-9p13.1a rs6477419 979943 rs7036799 38747881 9p24.3-9p21.1 146 3 Known ELAVL2 CDKN2A CDKN2B
11p15.5-11p11.2 rs2280544 194062 rs6485999 49615562 11p15.4 1 3 Known
17p13.3-17p11.2 rs4985615 172350 rs9783820 18601046 17p13.3a 21 2 Novel TUSC5
22q12.2-22q13.33 rs7289095 28983276 rs1001469 49428897 22q13.2-22q13.3 122 2 Known
aCommon alterations between pGBM and aGBM.
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D-type binding-protein 1 (CCNDBP1), and two poten-
tial tumor suppressor genes that regulate the p53 and
the Rb pathways are within this LOH peak.
Analysis of Regional Chromosomal Amplification
and Homozygous Deletions in GBMs
Only a small number of amplifications (defined as
4 copies or more) and homozygous deletions were
found in the pGBM samples. These were mainly in
regions close to the centromeres of Chrs 5, 7, 11, 19,
and 20, where typically no genes are found (Table 3).
In contrast, chromosomal amplifications were more fre-
quent in aGBMs (Tables 1 and 5). For example, all
aGBMs had amplification of 4p16, 5p11, 11q11, and
20p11.2, and five of six had amplification in 8p23 and
19p12-13.3. Further, as expected and previously
shown, epidermal growth factor receptor (EGFR) maps
to the largest SNP cluster of amplification in Chr7p12
in two-thirds of the primary aGBMs included in this
study (Table 5).25,26 In pGBM, a previously described
amplification of 7p12 including EGFR was observed
with a similar incidence to what is reported in the litera-
ture (2 of 18; 10.5%). However, a new amplification in
7q21-22 including CDK6 (Cyclin D Kinase 6) was seen
in 5 of 18 pGBMs. All tumors were supratentorial.
Interestingly, the latter is a known copy number variant
with a seemingly higher incidence in pGBM than in the
general population (5 of 18 versus 7 of 270; 26%
versus 3%, p , 0.001, Fisher exact test). For regional
homozygous chromosomal deletion, the most significant
finding was the deletion of an SNP cluster in aGBMs con-
taining interferon genes (IFNB1, IFNW1, IFNA21) that
are important in the induction of p53 gene expression
(Table 6).27 No homozygous deletions were observed
in pGBM.
Validation of CNAs Identified in This Study
In the absence of control DNA from the same individual
allowing confirmation that the CNAs we observed are
tumor-derived and not a normal variant, we cross-
referenced our data with the Database of Genomic
Variants and the CEU study.28,29 We additionally cross-
referenced our data for the most relevant CNAs with data
from a set of 1,363 control DNA analyzed with the
Illumina Human-Hap 300K platform.30 This allowed
us to identify some previously reported regions of
common structural polymorphisms in the general popu-
lation, further validating the other regions as tumor-
specific LOHs (Tables 2–6; see also Supplementary
Material, Tables S1 and S2). We also compared our
data with other available genotyping studies on
pHGAs16–18 and on aHGAs9,31,32 as the number of
adult cases used for comparison in this study is too few
to make a meaningful conclusion. We also compared
our data set to two publicly available 100K SNP array
data sets on aHGAs (NCBI GEO DataSets as GSE9635
and GSE6109 Records).13,33 Cross-referencing our
results with these data sets on aHGAs showed several
commonalities with previously published studies,
mainly for the adult patients included in our study
(Pearson correlation, r: 0.83 and Tables 1–6; see also
Supplementary Material, Table S1); however, only few
previously published CNAs were common with pGBM
(Pearson correlation, r: 0.21). We further validated the
data set against an independent data set of 9 pGBMs ana-
lyzed using another SNP platform, the Affymetrix 250K
SNP array that interrogates more than 200,000 loci and
has a similar average resolution of 15 kb,34 and obtained
concordant results for several CNAs, further validating
data obtained using the Illumina SNP arrays (see
Supplementary Material, Fig. S2).
We also arbitrarily chose a set of genes involved in
regions identified as homozygous deletions, LOH, or
Table 4. Identification of statistically overrepresented gene
ontologies (GOs) in the genes harbored in LOH regions analyzed
using the GOstat tool (http://gostat.wehi.edu.au/cgi-bin/
goStat.pl)
Gene Ontology Term p Number
of Genes
Total
Negative regulation of biological
process
3.80E211 119 1187
Cell-cycle process 5.08E211 89 809
System development 5.83E211 149 1623
Negative regulation of cellular
process
2.40E210 109 1095
Cellular developmental process 3.22E210 198 2389
Cell differentiation 3.22E210 198 2389
Regulation of cell proliferation 3.21E209 55 446
Transcription from RNA
polymerase II promoter
4.01E209 71 642
Regulation of cellular process 6.90E209 393 5660
Organ development 6.90E209 111 1183
Positive regulation of cellular
process
3.34E208 89 905
Cell development 5.44E208 155 1865
Regulation of cell cycle 5.71E208 65 599
Regulation of progression
through cell cycle
1.09E207 64 594
Positive regulation of biological
process
3.01E207 104 1152
Defense response to bacterium 2.14E206 18 99
Negative regulation of cell
proliferation
9.98E206 29 216
Cell death 1.12E205 79 862
Death 1.12E205 79 862
Protein kinase cascade 1.12E205 42 370
Apoptosis 1.12E205 75 807
Response to bacterium 1.43E205 18 107
Programmed cell death 1.48E205 75 813
Enzyme-linked receptor protein
signaling pathway
1.57E205 35 290
Cell migration 1.64E205 30 233
The complete database of annotated human genes was used as a
control set. Results were filtered to include only GOs with a
minimum path length of 5 and that fall under the biological
process segment of the GO hierarchy.
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DNA amplification in our data set and validated these
CNAs using quantitative real-time (qRT)-PCR on
DNA extracted from the same tumors (Tables 5 and
6). ELAVL2 (embryonic lethal, abnormal vision,
Drosophila-like 2), a gene located on 9p21, was within
a region of LOH in 5 of 18 pGBMs and potentially
deleted in 1 of 18. We confirmed these results using
qRT-PCR (Table 7). Chromosomal amplification in
pGBMs on 7q21-22, which contains CDK6, was ident-
ified in 5 of 18 tumors. CDK6 amplification was also
confirmed using qRT-PCR (Table 7).
Discussion
Understanding the molecular pathogenesis of pHGAs
requires a detailed cataloguing of all the genetic lesions
in the somatic lineage of this cancer. This study includes
the largest cohort of pGBMs analyzed for genomic
imbalances in tumor DNA and is the first to use high-
resolution SNP arrays. While further confirming that
aGBM and pGBM are genetically distinct cancers, we
provide a comprehensive whole-genome map of CNAs
for pGBM and identify, within regions of CNAs,
altered genes and pathways for further analysis
(Tables 1–7).
Our data show findings in common with available
array-based genomic studies on pGBM, including
ELAVL2, CDKN2A, and CDKN2B deletions that
have been reported in both pGBM and aGBM,
supporting the validity of our data set. However, pre-
vious studies on pHGAs used arrays that had a lower res-
olution of at least one log than the 100K and 250K
arrays used in this study.16 In these former studies, as
for BAC arrays, this resulted in a vast number of
genetic abnormalities going undetected. We uncover
herein several previously unidentified CNAs specific to
pediatric tumors that help provide insight into molecular
pathways involved in the genesis of pGBM. These CNAs
include LOH in 15q15.1-15q23 and 17p13-17p11.2
and amplification of 7q21-22 and 1q43-44. Even if
some CNAs are common to the pediatric and adult
setting, their overall incidence will differ whether they
occur in children or in adults. When we reviewed pub-
lished data sets on aHGAs, commonalities with our find-
ings on pGBM included LOH of 22q17p and 9p,
whereas LOH of 3p21 and 10q21 and amplification of
7q, 2p, 9p, and 10q seemed specific to pGBM (see
Supplementary Material, Table S2). As an added
example, amplification of 7p12 including EGFR is a fre-
quent event in primary aGBMs (45%).9,35 We and
others16,36 show amplification of 7p12 including
EGFR in only rare cases of pediatric GBMs (less than
10%). Conversely, amplification of 7q21-22 including
CDK6 is a rare event in aHGAs (one case report),
whereas it was present in 5 of 18 pGBMs. In addition,
as a consequence of the higher resolution of the arrays
we used, the genetic interval subject to alteration in
tumors will differ in pediatric and adult samples in
many cases. For example, 10q LOH/deletion will
Table 5. Amplifications in pGBM and aGBM
Cytogenetic
Band
Locus (Mb) Minimal region Genes Number of
Tumors
Known or
Novel
Interesting
Genes
Start SNP Position End SNP Position
Amplifications in pGBM
1q 1q43-1q44 26 2 Novel AKT3
2p24.3 rs12616227 14424553 rs300168 17884078 2p24.3 15 3 Known MYCN
3q26-3q29 rs7638716 174896221 rs6770002 199198093 3q26.31-3q26.33 34 2 Novel PIK3CA,
NGL1
4q12 rs11734039 54105356 rs7692791 55821167 4q12 11 2 Known PDGFRa, KIT
5p33-5p15 rs4956990 236134 rs2578553 5502367 5p15.33-5p15.2 62 2 Novel TPPP
7p22.3-7p11.2a rs7786069 160449 rs4947882 54032344 7p22.3-7p11.2 417 2 Known EGFR
7q11.21-7q33b rs2198391 61491258 rs3735019 137020053 7q21.13-7q21.3 23 5 Novel CDK6
7q11.21-7q33 rs2198391 61491258 rs3735019 137020053 7q31.2-7q33 163 4 Novel
9p24.3-9p13 rs999924 1322257 rs2799738 38468670 9p13.3-9p13.1 122 3 Novel
9q 9q33.1-9q34.3 265 2 Novel
10p12.31-10p12 rs1055340 16595534 rs751006 26145481 10p12.2-10p12.1 3 2 Novel OTUD1
10q22.2-10q26.3 rs4746308 76999278 rs2515641 135240243 10q22.2-10q26.3 516 3 Novel PTEN
17q21-17q25.3 rs8074034 44287297 rs599314 78321361 17q21.33-17q22 73 2 Novel
Amplifications in aGBMs
3p12.3-3p11.2 rs4258921 81083700 rs1521800 90084278 3p12.3-3p11.2 21 1 Novel EPHA3
7p15.2-7p11.1 rs10259620 26975529 rs6974091 57689510 7p15.2-7p14.1 38 2 Novel CREB5
7p12a rs1454520 54455112 rs7796351 55230615 7p11 6 2 Known EGFR
12q14.3-12q15 rs1797404 64866345 rs7973221 69380480 12q14.3-12q15 41 1 Novel NGFR
Seventeen (94.4%) of the 18 pediatric patients and all the 6 adult patients have at least one amplification. All the samples have at least 2
loci with amplification or homozygous deletion.
aCommon alterations between pGBM and aGBM.
bKnown CNA with a much higher incidence than the one found in the normal population.
Qu et al.: SNP arrays in pediatric high-grade astrocytomas
NEURO-ONCOLOGY † F E B R U A R Y 2 0 1 0 159
Table 6. Homozygous deletions in pGBM and aGBM
Cytogenetic Band Locus (Mb) Minimal Region Genes Number
of Tumors
Known or
Novel
Interesting Genes
Start SNP Position End SNP Position
Deletions in pGBM
1q24.2-1q31.1 rs2901029 165831827 rs1011726 187652124 1q24.2-1q31.1 195 1 Novel FASLG
2q21.1-2q22.2 rs1918615 140631475 rs1465839 143468685 2q21.1-2q22.2 3 1 Novel LOC730114
5q14.2-5q22.1 rs2656989 82226475 rs6881837 111305383 5q14.2-5q22.1 111 1 Novel
6q24.3 rs1832378 145733157 rs1039085 147677240 6q24.3 13 1 Novel RAB32
9p23 rs419387 10050049 rs10809546 11642121 9p23 3 1 Novel
9p21.2a rs1475660 20746547 rs1197944 27991944 9p21.2 48 1 Known ELAVL2, CDKN2A-2B
10q21.3-10q22.1 rs747942 71006472 rs10823922 73852923 10q21.3-10q22.1 35 1 Novel CBARA1
11q11-11q22.3 rs9666583 54865587 rs7112835 108318814 11q11-11q22.3 858 1 Novel
11q22.3-11q23.1 rs7112835 108318814 rs1293344 111542594 11q22.3-11q23.1 37 1 Novel ARHGAP20
16q23.2-16q23.3 rs7204972 79379066 rs9922131 81700946 16q23.2-16q23.3 16 1 Novel PLCG2
17q11.2 rs1061346 26138355 rs9915569 27490232 17q11.2 24 1 Novel OMG
18q23 rs2196736 74449768 rs4798947 76064957 18q23 19 1 Novel KNCG2
21q11.2-21q21.3 rs2742158 13560787 rs3737413 26270243 21q11.2-21q21.3 64 1 Novel BIC
Deletions in aGBMs
9p21.3 rs1556475 20811287 rs2939 21156004 9p21 5 3 Novel INFB1, INFA21
14q23.2 rs1695770 64284919 rs8015408 66216433 14q23.2 19 1 Novel MAX, YBX1P1
14q24.1-14q24.2 rs8016781 68963945 rs6574074 71945439 14q24.1-14q24.2 26 1 Novel SIPA1L1
Fifteen (83.3%) of the 18 pediatric patients and all the 6 adult patients have at least one homozygous deletion. All the samples have at least 2 loci with amplification or homozygous deletion.
Homozygous deletion in 10q including PTEN was found in 4 of 6 adult tumors and is not included as it is a known alteration.
aCommon alterations between pGBM and aGBM.
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Table 7. Validation of Illumina Infinium 1 SNP-array data using qRT-PCR on selected genes
Illumina data Normalized ratio Normalized STD
CDK6
P1 Normal copy number 1.24 0.52
P2 Amplification 114.45 7.63
P3 Amplification 42.55 7.26
P5 Amplification 3.80 0.86
P7 Normal copy number 1.34 0.36
P11 Amplification 2.63 0.38
P13 Normal copy number 1.27 0.28
P15 Normal copy number 1.20 0.31
P16 Amplification 7.82 0.27
ELAVL2
P13 LOH 0.40 0.13
P15 LOH 0.50 0.07
P12 LOH 0.42 0.14
P11 Homozygous deletion 0.19 0.04
P1 LOH 0.46 0.11
P7 LOH 0.48 0.16
P2 Normal copy number 1.20 0.17
P4 Normal copy number 0.80 0.23
P6 Normal copy number 1.10 0.32
To validate results we obtained following the analysis of data from SNP arrays, we selected previously identified genes in high-grade
astrocytomas that were included in regions showing chromosomal amplification (CDK6, amplification of Ch 7q21 in 5 tumors P2–P3–
P5–P11–P16) or LOH or homozygous deletion (ELAVL2, LOH in P1–P7–P13–P15–P12, complete deletion in P11) and performed
qRT-PCR on DNA extracted from the same tumors and from other tumors included in this study and showing no copy number change for
these regions. Normalized ratio obtained using qRT-PCR was interpreted as follows: ,0.2 homozygous deletion; 0.4, X, 0.6 LOH; .2
amplification. Pediatric high-grade astrocytomas were numbered from 1 to 18 for clarity issues with the suffix P for pediatric.
CDK6, cyclin D kinase 6; ELAVL2, embryonic lethal, abnormal vision, drosophila-like 2; STD, standard deviation.
Fig. 1. Unsupervised hierarchical clustering of 24 GBMs (18 pediatric and 6 adult) and 1 control normal brain (CB). We used statistically
significant CNAs present in at least one sample as data input (Welsch t-test, p, 0.001) and separated our data set accordingly. Pediatric
(P) samples clustered separately from adult samples (A) and from the CB. DNA from one pediatric sample P1 was extracted from two
separate parts of the same tissue sample. DNA from both extractions was independently subjected to whole-genome amplification prior
to analysis on the 100K SNP array platform. P1a and P1b clustered similarly showing the reproducibility of the analysis of genome
profiling. Primary adult glioblastoma (Ap) clustered separately from secondary adult glioblastoma (As).
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include the PTEN gene (10q23.31) in adults whereas the
genetic interval will be different in children and LOH on
10q will not include it (10q21.3-10q22.1).
Cell-cycle abnormalities, including alterations of the
p53 and the RB1 pathways, play an important role in
the genesis of HGAs, including pHGAs.20,26 As shown
in the analysis of genes included in the CNA regions
(Tables 3–6) and by the gene ontology analysis
(Table 4), genes associated with the cell-cycle check-
points and genes involved in the regulation of cell-cycle
and cell-death pathways are the major targets of LOHs
in pGBM. For example, we identified recurrent LOHs
in several tumors that encompass several genes including
H76p, TP53BP1, and CCNDBP1 on 15p (Table 3).
H76p is associated with the g-tubulin complexes and
may participate in the nucleation process.37 TP53BP1
is a conserved checkpoint protein with properties of a
DNA double-strand break sensor. It binds to the
central domain of p53, enhancing transactivation, and
its deletion may play an important role by impairing
function of tumor protein p53 (TP53).38 CCNDBP1 is
a helix–loop–helix leucine zipper protein, recently
identified as a novel tumor suppressor in epithelial
cancers, showing LOH and/or deletions on Chr15.39 It
decreases the levels of Cyclin D expression, reducing
the phosphorylation of RB1, thus regulating the RB1
pathway and cell growth.39
The rare gene containing regions showing genomic
amplification in pGBM included 7q21-22 in 5 pGBMs
(Table 5). This region is interesting from two stand-
points. It includes CDK6, which encodes for a kinase
also regulating the RB1 pathway. Amplification of
CDK6 in this subset of pGBM was validated by
qRT-PCR (Table 7) and has not been previously
reported in pHGAs. In aHGAs, amplification of CDK6
has been reported in only one patient, whereas its over-
expression, without genetic amplification, is more
common (40%). Secondly, a CNA found with statisti-
cally higher frequency in a given tumor is likely a germ-
line predisposition to the tumor. 7q21-22 seems to be
amplified in a small percentage of the normal popu-
lation, and the higher incidence of its amplification in
pGBM, when further confirmed, may indicate an
association of a common variant with susceptibility to
these tumors (Table 5).
Little is known on the genetics of pGBM and our
study fills an important gap in understanding this pedi-
atric brain tumor. Moreover, the considerable wealth
of information on the molecular genetics of aHGA is
often projected onto the pediatric population without
critical comparison between these two different disease
contexts. Our data document how profound these differ-
ences are. We propose that analyses such as the one pre-
sented in this study may ultimately guide mapping of
oncogenic signaling networks unique to pGBM, identifi-
cation of the related therapeutic predictors and targets,
and development of more effective therapies.
Alteration of copy number for genes involved in p53
and the RB pathways including, for example, amplifica-
tion of CDK6, or LOH of CCNDBP1 or TP53BP1, are
some of the interesting findings unraveled in our data set
that will help shed light on the unique molecular patho-
genesis of this disease, providing hope of developing new
therapeutic strategies to improve survival in a devastat-
ing cancer.
Supplementary Material
Supplementary material is available at Neuro-Oncology
Journal online.
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